Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,John Allan, MD

Panelists discuss how several studies evaluating bispecific therapies in earlier lines of therapy for diffuse large B-cell lymphoma and follicular lymphoma suggest that patients with high-risk or relapsed/refractory disease are most likely to benefit from these treatments.

EP: 1.ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

EP: 2.Emerging Data for Odronextamab in DLBCL

EP: 3.Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

Now Viewing

EP: 4.Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

Video content above is prompted by the following:

Several studies are evaluating the use of bispecific therapies in earlier lines of therapy for both diffuse large B-cell lymphoma and follicular lymphoma. What patient populations are most likely to benefit from bispecific therapies in earlier lines of therapy?